Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

De novo phosphatidylcholine synthesis is required for autophagosome membrane formation and maintenance during autophagy.

Andrejeva G, Gowan S, Lin G, Wong Te Fong AL, Shamsaei E, Parkes HG, Mui J, Raynaud FI, Asad Y, Vizcay-Barrena G, Nikitorowicz-Buniak J, Valenti M, Howell L, Fleck RA, Martin LA, Kirkin V, Leach MO, Chung YL.

Autophagy. 2019 Sep 13:1-17. doi: 10.1080/15548627.2019.1659608. [Epub ahead of print]

PMID:
31517566
2.

Microbiota and radiotherapy-induced gastrointestinal side-effects (MARS) study: a large pilot study of the microbiome in acute and late radiation enteropathy.

Reis Ferreira M, Andreyev J, Mohammed K, Truelove L, Gowan SM, Li J, Gulliford SL, Marchesi J, Dearnaley DP.

Clin Cancer Res. 2019 Jul 25. pii: clincanres.0960.2019. doi: 10.1158/1078-0432.CCR-19-0960. [Epub ahead of print]

PMID:
31345839
3.

Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma.

Al-Saffar NMS, Troy H, Wong Te Fong AC, Paravati R, Jackson LE, Gowan S, Boult JKR, Robinson SP, Eccles SA, Yap TA, Leach MO, Chung YL.

Br J Cancer. 2018 Oct;119(9):1118-1128. doi: 10.1038/s41416-018-0242-3. Epub 2018 Oct 31.

4.

Key word signing: Parents' experiences of an unaided form of augmentative and alternative communication (Lámh).

Glacken M, Healy D, Gilrane U, Gowan SH, Dolan S, Walsh-Gallagher D, Jennings C.

J Intellect Disabil. 2019 Sep;23(3):327-343. doi: 10.1177/1744629518790825. Epub 2018 Aug 19.

PMID:
30122092
5.

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma.

Tucker ER, Tall JR, Danielson LS, Gowan S, Jamin Y, Robinson SP, Banerji U, Chesler L.

Mol Oncol. 2017 Aug;11(8):996-1006. doi: 10.1002/1878-0261.12069. Epub 2017 May 31.

6.

Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases.

Clarke PA, Ortiz-Ruiz MJ, TePoele R, Adeniji-Popoola O, Box G, Court W, Czasch S, El Bawab S, Esdar C, Ewan K, Gowan S, De Haven Brandon A, Hewitt P, Hobbs SM, Kaufmann W, Mallinger A, Raynaud F, Roe T, Rohdich F, Schiemann K, Simon S, Schneider R, Valenti M, Weigt S, Blagg J, Blaukat A, Dale TC, Eccles SA, Hecht S, Urbahns K, Workman P, Wienke D.

Elife. 2016 Dec 9;5. pii: e20722. doi: 10.7554/eLife.20722.

7.

A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.

Dale T, Clarke PA, Esdar C, Waalboer D, Adeniji-Popoola O, Ortiz-Ruiz MJ, Mallinger A, Samant RS, Czodrowski P, Musil D, Schwarz D, Schneider K, Stubbs M, Ewan K, Fraser E, TePoele R, Court W, Box G, Valenti M, de Haven Brandon A, Gowan S, Rohdich F, Raynaud F, Schneider R, Poeschke O, Blaukat A, Workman P, Schiemann K, Eccles SA, Wienke D, Blagg J.

Nat Chem Biol. 2015 Dec;11(12):973-980. doi: 10.1038/nchembio.1952. Epub 2015 Oct 26.

8.

Effects of anti-proliferative lichen metabolite, protolichesterinic acid on fatty acid synthase, cell signalling and drug response in breast cancer cells.

Bessadóttir M, Skúladóttir EÁ, Gowan S, Eccles S, Ögmundsdóttir S, Ogmundsdóttir HM.

Phytomedicine. 2014 Oct 15;21(12):1717-24. doi: 10.1016/j.phymed.2014.08.006. Epub 2014 Sep 16.

PMID:
25442282
9.

Discovery and validation of gene-linked diagnostic SNP markers for assessing hybridization between Largemouth bass (Micropterus salmoides) and Florida bass (M. floridanus).

Li C, Gowan S, Anil A, Beck BH, Thongda W, Kucuktas H, Kaltenboeck L, Peatman E.

Mol Ecol Resour. 2015 Mar;15(2):395-404. doi: 10.1111/1755-0998.12308. Epub 2014 Aug 11.

PMID:
25047482
10.

Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.

Renshaw J, Taylor KR, Bishop R, Valenti M, De Haven Brandon A, Gowan S, Eccles SA, Ruddle RR, Johnson LD, Raynaud FI, Selfe JL, Thway K, Pietsch T, Pearson AD, Shipley J.

Clin Cancer Res. 2013 Nov 1;19(21):5940-51. doi: 10.1158/1078-0432.CCR-13-0850. Epub 2013 Aug 5.

11.

A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma.

Box C, Mendiola M, Gowan S, Box GM, Valenti M, Brandon Ade H, Al-Lazikani B, Rogers SJ, Wilkins A, Harrington KJ, Eccles SA.

Eur J Cancer. 2013 Jul;49(11):2512-21. doi: 10.1016/j.ejca.2013.03.011. Epub 2013 Apr 10.

PMID:
23582742
12.

Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation.

Vinci M, Gowan S, Boxall F, Patterson L, Zimmermann M, Court W, Lomas C, Mendiola M, Hardisson D, Eccles SA.

BMC Biol. 2012 Mar 22;10:29. doi: 10.1186/1741-7007-10-29.

13.

Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β.

Bielen A, Perryman L, Box GM, Valenti M, de Haven Brandon A, Martins V, Jury A, Popov S, Gowan S, Jeay S, Raynaud FI, Hofmann F, Hargrave D, Eccles SA, Jones C.

Mol Cancer Ther. 2011 Aug;10(8):1407-18. doi: 10.1158/1535-7163.MCT-11-0205. Epub 2011 Jun 9.

14.

Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma.

Gaspar N, Sharp SY, Eccles SA, Gowan S, Popov S, Jones C, Pearson A, Vassal G, Workman P.

Mol Cancer Ther. 2010 May;9(5):1219-33. doi: 10.1158/1535-7163.MCT-09-0683.

15.

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941.

Raynaud FI, Eccles SA, Patel S, Alix S, Box G, Chuckowree I, Folkes A, Gowan S, De Haven Brandon A, Di Stefano F, Hayes A, Henley AT, Lensun L, Pergl-Wilson G, Robson A, Saghir N, Zhyvoloup A, McDonald E, Sheldrake P, Shuttleworth S, Valenti M, Wan NC, Clarke PA, Workman P.

Mol Cancer Ther. 2009 Jul;8(7):1725-38. doi: 10.1158/1535-7163.MCT-08-1200. Epub 2009 Jul 7.

16.

NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.

Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, Patterson L, de Haven Brandon A, Gowan S, Boxall F, Aherne W, Rowlands M, Hayes A, Martins V, Urban F, Boxall K, Prodromou C, Pearl L, James K, Matthews TP, Cheung KM, Kalusa A, Jones K, McDonald E, Barril X, Brough PA, Cansfield JE, Dymock B, Drysdale MJ, Finch H, Howes R, Hubbard RE, Surgenor A, Webb P, Wood M, Wright L, Workman P.

Cancer Res. 2008 Apr 15;68(8):2850-60. doi: 10.1158/0008-5472.CAN-07-5256.

17.

Application of meso scale technology for the measurement of phosphoproteins in human tumor xenografts.

Gowan SM, Hardcastle A, Hallsworth AE, Valenti MR, Hunter LJ, de Haven Brandon AK, Garrett MD, Raynaud F, Workman P, Aherne W, Eccles SA.

Assay Drug Dev Technol. 2007 Jun;5(3):391-401.

PMID:
17638539
18.

Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.

Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S, Henley A, Di-Stefano F, Ahmad Z, Guillard S, Bjerke LM, Kelland L, Valenti M, Patterson L, Gowan S, de Haven Brandon A, Hayakawa M, Kaizawa H, Koizumi T, Ohishi T, Patel S, Saghir N, Parker P, Waterfield M, Workman P.

Cancer Res. 2007 Jun 15;67(12):5840-50.

19.

Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis.

Sanderson S, Valenti M, Gowan S, Patterson L, Ahmad Z, Workman P, Eccles SA.

Mol Cancer Ther. 2006 Mar;5(3):522-32.

20.

Evaluation of by disubstituted acridone derivatives as telomerase inhibitors: the importance of G-quadruplex binding.

Harrison RJ, Reszka AP, Haider SM, Romagnoli B, Morrell J, Read MA, Gowan SM, Incles CM, Kelland LR, Neidle S.

Bioorg Med Chem Lett. 2004 Dec 6;14(23):5845-9.

PMID:
15501053
21.

Trisubstituted acridine derivatives as potent and selective telomerase inhibitors.

Harrison RJ, Cuesta J, Chessari G, Read MA, Basra SK, Reszka AP, Morrell J, Gowan SM, Incles CM, Tanious FA, Wilson WD, Kelland LR, Neidle S.

J Med Chem. 2003 Oct 9;46(21):4463-76.

PMID:
14521409
22.

A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity.

Gowan SM, Harrison JR, Patterson L, Valenti M, Read MA, Neidle S, Kelland LR.

Mol Pharmacol. 2002 May;61(5):1154-62.

PMID:
11961134
23.

Molecular profiles of group B streptococcal surface protein antigen genes: relationship to molecular serotypes.

Kong F, Gowan S, Martin D, James G, Gilbert GL.

J Clin Microbiol. 2002 Feb;40(2):620-6.

24.

Antitumor polycyclic acridines. 8.(1) Synthesis and telomerase-inhibitory activity of methylated pentacyclic acridinium salts.

Heald RA, Modi C, Cookson JC, Hutchinson I, Laughton CA, Gowan SM, Kelland LR, Stevens MF.

J Med Chem. 2002 Jan 31;45(3):590-7.

PMID:
11806711
25.

Serotype identification of group B streptococci by PCR and sequencing.

Kong F, Gowan S, Martin D, James G, Gilbert GL.

J Clin Microbiol. 2002 Jan;40(1):216-26.

26.

Extension of the Lancefield classification for group A streptococci by addition of 22 new M protein gene sequence types from clinical isolates: emm103 to emm124.

Facklam RF, Martin DR, Lovgren M, Johnson DR, Efstratiou A, Thompson TA, Gowan S, Kriz P, Tyrrell GJ, Kaplan E, Beall B.

Clin Infect Dis. 2002 Jan 1;34(1):28-38. Epub 2001 Nov 26.

PMID:
11731942
27.

Potent inhibition of telomerase by small-molecule pentacyclic acridines capable of interacting with G-quadruplexes.

Gowan SM, Heald R, Stevens MF, Kelland LR.

Mol Pharmacol. 2001 Nov;60(5):981-8.

PMID:
11641426
28.

Structure-based design of selective and potent G quadruplex-mediated telomerase inhibitors.

Read M, Harrison RJ, Romagnoli B, Tanious FA, Gowan SH, Reszka AP, Wilson WD, Kelland LR, Neidle S.

Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):4844-9. Epub 2001 Apr 17.

29.

A novel inhibitor of human telomerase derived from 10H-indolo[3,2-b]quinoline.

Caprio V, Guyen B, Opoku-Boahen Y, Mann J, Gowan SM, Kelland LM, Read MA, Neidle S.

Bioorg Med Chem Lett. 2000 Sep 18;10(18):2063-6.

PMID:
10999471
30.

Design, synthesis and evaluation of human telomerase inhibitors based upon a tetracyclic structural motif.

Perry PJ, Gowan SM, Read MA, Kelland LR, Neidle S.

Anticancer Drug Des. 1999 Aug;14(4):373-82.

PMID:
10625930
31.

Molecular modeling studies on G-quadruplex complexes of telomerase inhibitors: structure-activity relationships.

Read MA, Wood AA, Harrison JR, Gowan SM, Kelland LR, Dosanjh HS, Neidle S.

J Med Chem. 1999 Nov 4;42(22):4538-46.

PMID:
10579817
32.

Human telomerase inhibition by substituted acridine derivatives.

Harrison RJ, Gowan SM, Kelland LR, Neidle S.

Bioorg Med Chem Lett. 1999 Sep 6;9(17):2463-8.

PMID:
10498189
33.

2,7-Disubstituted amidofluorenone derivatives as inhibitors of human telomerase.

Perry PJ, Read MA, Davies RT, Gowan SM, Reszka AP, Wood AA, Kelland LR, Neidle S.

J Med Chem. 1999 Jul 15;42(14):2679-84.

PMID:
10411488
34.

Human telomerase inhibition by regioisomeric disubstituted amidoanthracene-9,10-diones.

Perry PJ, Reszka AP, Wood AA, Read MA, Gowan SM, Dosanjh HS, Trent JO, Jenkins TC, Kelland LR, Neidle S.

J Med Chem. 1998 Nov 19;41(24):4873-84.

PMID:
9822556
35.

1,4- and 2,6-disubstituted amidoanthracene-9,10-dione derivatives as inhibitors of human telomerase.

Perry PJ, Gowan SM, Reszka AP, Polucci P, Jenkins TC, Kelland LR, Neidle S.

J Med Chem. 1998 Aug 13;41(17):3253-60.

PMID:
9703471
36.

Cloning of guinea pig surfactant protein A defines a distinct cellular distribution pattern within the lung.

Yuan HT, Gowan S, Kelly FJ, Bingle CD.

Am J Physiol. 1997 Oct;273(4):L900-6. doi: 10.1152/ajplung.1997.273.4.L900.

PMID:
9357868
37.
38.
39.

Supplemental Content

Support Center